H ealth Canada has conditionally approved the drug lecanemab to slow early-stage Alzheimer's disease, raising questions about its effectiveness and availability in Canada.
Lecanemab is a lab-made antibody given by intravenous infusion. It targets the buildup of amyloid plaque in the brain, a h allmark of Alzheimer's disease.
Lecanemab is not a cure and cannot rev erse the disease or restore lost memories.
The Alzheimer Society of Canada calls it the first disease-modifying Alzheimer's treatment approved for use in the country. Current medications mitigate symptoms rather than change the course of the disease.
How well the dru g
Continue Reading on CBC News
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.